ClinicalTrials.gg
CompletedNCT07065058Updated Mar 31, 2026

A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects

A Phase 1 interventional study of Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin in Obesity &Amp; Overweight, sponsored by Vincentage Pharma Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Vincentage Pharma Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Enrollment
462nd of 502
24 · median 120
Started
2025
with 113 others
Phase 1
93 of 600
29 open now
Registered
379th of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 462nd largest by enrollment of the 502 interventional ones that give a count, is one of 114 that started in 2025, is one of 93 in phase 1, and was the 379th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy, overweight, and obese subjects. The primary objective is to evaluate the effect of orally administered VCT220 tablets on the pharmacokinetics and safety of repaglinide , rosuvastatin, and digoxin.

A total of 24 subjects will be enrolled. Repaglinide is administered alone on Day 1 and coadministered with VCT220 on Day 72. Rosuvastatin and digoxin are administered together on Day 2 and again on Day 73 with VCT220. VCT220 will be titrated from 20 mg to 160 mg once daily from Day 9 to Day 78.

All study drugs are given under controlled fed or fasting conditions, with standardized water and meal restrictions. Intensive PK sampling will be conducted around dosing to assess any drug-drug interactions. Safety assessments will be conducted throughout the study.

Read the detailed description

This is a single-center, open-label, single-arm, fixed-sequence Phase I clinical study designed to evaluate the effect of orally administered VCT220 tablets on the pharmacokinetics (PK) and safety of repaglinide, rosuvastatin, and digoxin in healthy, overweight, and obese adult subjects. These three drugs are probe substrates for key drug transporters: repaglinide for OATP1B1/OATP1B3, rosuvastatin for BCRP, and digoxin for P-glycoprotein (P-gp).

A total of 24 subjects will be enrolled. On Day 1, subjects receive a single dose of repaglinide 0.5 mg under fasting conditions. On Day 2, rosuvastatin 10 mg and digoxin 0.25 mg are co-administered under fed conditions. From Day 9 to Day 78, subjects will receive VCT220 orally once daily after breakfast in an ascending dose regimen: 20 mg, 40 mg, 80 mg, 120 mg, and finally 160 mg, titrated every 2 weeks.

On Day 72, repaglinide is administered again under fasting conditions, now in the presence of steady-state VCT220. On Day 73, rosuvastatin and digoxin are administered again under fed conditions with VCT220. Water intake is restricted within 1 hour before and after dosing, and standardized meals are provided to control for food effects.

Serial blood samples will be collected before and after dosing for PK assessments. The primary endpoints are the PK parameters (Cmax, AUC) of the probe drugs with and without VCT220. Safety will be evaluated throughout the study via clinical assessments, laboratory tests, vital signs, ECGs, and adverse event monitoring

03

Conditions studied

  • Obesity &Amp; Overweight
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be fully informed of the purpose, content, procedures, and potential adverse reactions of the study, voluntarily agree to participate, and sign the form (ICF) prior to any study-related procedures.
  2. Male and female subjects aged between 18 and 65 years (inclusive).
  3. Male subjects must weigh ≥50.0 kg and female subjects ≥45.0 kg, with a (BMI) ≥20 kg/m² [BMI = weight (kg) / height² (m²)].
  4. Subjects must have no plans for childbearing from the time of signing the ICF until 3 months after the last dose of the study drug and must voluntarily agree to use effective ; subjects must also have no plans to donate sperm or eggs during this period.
  5. Subjects must be able to communicate well with the investigators, and understand and comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Any of the following laboratory abnormalities at screening:

    1. ≥ 6.5%;
    2. Fasting plasma glucose (FPG) ≥ 7.0 mmol/L;
    3. Estimated (eGFR) \< 90 mL/min/1.73m² (calculated by CKD-EPI formula);
    4. and/or AST > 1.5× (ULN);
    5. Total (TBIL) > 1.5× ULN;
    6. Serum amylase or lipase > 1.5× ULN;
    7. Calcitonin ≥ 1.0× ULN;
    8. \< 110 g/L (males) or \< 100 g/L (females).
  2. Positive test results for any of the following: , -Ab, -Ab, or TP-Trust (syphilis).
  3. 12-lead during screening showing second- or third-degree atrioventricular block, long syndrome, QTcF ≥ 450 ms (males) or ≥ 470 ms (females) (QTcF = QT/RR\^0.33), bundle branch block, Wolff-Parkinson-White syndrome, or other arrhythmias (excluding sinus arrhythmia), or ECG findings deemed clinically significant by the investigator.
  4. Known allergy to VCT220, repaglinide, rosuvastatin, or digoxin, or history of allergy to two or more drugs or foods.
  5. Presence of clinically significant diseases requiring exclusion, including but not limited to disorders of the nervous, cardiovascular (unless deemed acceptable by the investigator), hematologic, lymphatic, immune, digestive, urinary, respiratory, metabolic, or skeletal systems.
  6. History or current diagnosis of pancreatitis (acute or chronic), history of acute gallbladder disease (except for those who have undergone cholecystectomy), or clinically significant findings on baseline abdominal ultrasound.
  7. Diagnosis of type 1, type 2, or other specific types of diabetes.
  8. Use of GLP-1 receptor agonists within 6 months before screening.
  9. Swallowing difficulties or gastrointestinal diseases affecting drug absorption (e.g., diarrhea, vomiting, IBD, acute gastroenteritis, peptic ulcer, or significant GI dysfunction with impaired absorption).
  10. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
  11. Major depressive disorder or other severe psychiatric disorders within 2 years prior to screening.
  12. Surgery within 3 months prior to screening, planned surgery during the study, or history of surgeries that may affect ADME of drugs.
  13. History of drug abuse or illicit drug use within 12 months prior to screening, or positive drug screen.
  14. Participation in another drug/device trial within 3 months before screening or plans to participate in another clinical trial during the study.
  15. Use of oral within 30 days before screening (female subjects).
  16. Use of long-acting estrogen or progestin injections, hormone-releasing IUDs, or implants within 6 months prior to screening (female subjects).
  17. Blood donation (including components) or significant blood loss ≥400 mL, transfusion, or use of blood products within 3 months before screening.
  18. Use of any prescription medications (especially those affecting , CYP2C8, CYP2C9, CYP2C19), over-the-counter drugs, herbal supplements, or dietary supplements within 14 days prior to first dosing, or plan to use them during the study.
  19. Smoking more than 5 cigarettes per day within 3 months before screening, or inability to abstain from tobacco products during the study.
  20. Alcohol consumption >14 units/week (1 unit ≈ 360 mL beer at 5% alcohol, 45 mL liquor at 40%, or 150 mL wine at 12%) within 3 months before screening, inability to abstain during the study, or positive alcohol breath test (>0 mg/100 mL).
  21. Excessive consumption of tea, coffee, or other caffeinated beverages (more than 8 cups/day; 1 cup = 250 mL) within 3 months prior to screening, or consumption of any caffeine within 24 hours before dosing, or unwillingness to abstain from caffeine during the study.
  22. Consumption of foods or beverages that may affect drug metabolism (e.g., dragon fruit, mango, grapefruit, pomelo, orange) within 2 days before first dose, or unwillingness to avoid such items during the study.
  23. Special dietary requirements that prevent adherence to standardized meals.
  24. Positive pregnancy test at screening, breastfeeding, or fertile women who had unprotected intercourse within 30 days prior to screening.
  25. History of needle phobia, blood phobia, or intolerance to venipuncture.
  26. Vaccination within 14 days prior to screening or planned vaccination during the study.
  27. Clinically significant abnormalities on physical examination, ECG, labs (CBC, urinalysis, biochemistry, coagulation, fasting C-peptide), abdominal ultrasound, or chest X-ray (PA view), as assessed by the investigator.
  28. Vital signs outside the acceptable range at screening and still abnormal upon repeat measurement.
  29. Any other condition that the investigator deems makes the subject unsuitable for study participation.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Participant Group

    During the monotherapy phase, subjects receive repaglinide, rosuvastatin, and digoxin. After a 1-week washout period, VCT220 is administered starting from 20 mg and titrated up to 160 mg, followed by repeat administration of repaglinide, rosuvastatin, and digoxin.

    Drug: Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin

Interventions

  • DrugDrug: VCT220, Repaglinide, Rosuvastatin, and Digoxin

    Single dose of Repaglinide at Day 2, Rosuvastatin and Digoxin at Day 3 Orally VCT220 once daily from Day 9 to Day 78, titrated from 20mg to 160mg. Co-administrated Repaglinide at Day 72, co-administrated Rosuvastatin and Digoxin at Day 73

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Repaglinide

    Time frame: 1h before dosing, 0.25 h、0.5 h、1 h、1.5 h、2 h、3 h、4 h、6 h、8 h、12 h and 24 h post dosing

  2. Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Rosuvastatin

    Time frame: 1h before dosing, 0.5 h、1 h、2 h、3 h、4 h、6 h、8 h、10 h、12 h、16 h、24 h、48 h、72 h、96 h and 120 h post dosing

  3. Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Digoxin

    Time frame: 1h before dosing, 0.5 h、1 h、2 h、3 h、4 h、6 h、8 h、10 h、12 h、16 h、24 h、48 h、72 h、96 h and 120 h post dosing

  4. Maximum Observed Concentration (Cmax) of Repaglinide

    Time frame: 1h before dosing, 0.25 h、0.5 h、1 h、1.5 h、2 h、3 h、4 h、6 h、8 h、12 h and 24 h post dosing

  5. Maximum Observed Concentration of Rosuvastatin

    Time frame: 1h before dosing, 0.5 h、1 h、2 h、3 h、4 h、6 h、8 h、10 h、12 h、16 h、24 h、48 h、72 h、96 h and 120 h post dosing

  6. Maximum Observed Concentration (Cmax) of Digoxin

    Time frame: 1h before dosing, 0.5 h、1 h、2 h、3 h、4 h、6 h、8 h、10 h、12 h、16 h、24 h、48 h、72 h、96 h and 120 h post dosing

Secondary outcomes

  1. Safety of VCT220

    Adverse events \[TEAEs, SAEs\], dose interruption, or discontinuation, vital signs (heart rate \[beats/min\], and changes in laboratory parameters (chemistry, hematology, urinalysis, coagulation).

    Time frame: From day 0 to day 78

07

Study locations

1 site
  • West China Second University Hospital
    Chengdu, Sichuan 610041, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Jul 2025, 0 months.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 0 months is below that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 15, 2025
StartActual
Jul 1, 2025
Primary completionActual
Jul 11, 2025
CompletionActual
Aug 11, 2025
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07065058
Lead sponsor
Vincentage Pharma Co., Ltd
Responsible party
Sponsor
First posted
Jul 15, 2025
Start date
Jul 1, 2025
Primary completion
Jul 11, 2025
Completion
Aug 11, 2025
Last update
Mar 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion